Kaleido Biosciences Inc expected to post a loss of 54 cents a share - Earnings Preview

Kaleido Biosciences

29/10/2021 18:24

* Kaleido Biosciences Inc  KLDO.OQ   KLDO.O  is expected to show
a fall in quarterly revenue when it reports results on November
1 (estimated). 
* The Bedford, Massachusetts-based company is expected to report
 a 64.7% decrease in revenue to $170 thousand from $482 thousand
a year ago, according to the mean estimate from 5 analysts,
based on Refinitiv data. 
​* Refinitiv's mean analyst estimate for Kaleido Biosciences Inc
is for a loss of 54 cents per share. For the same quarter last
year, the company reported a loss of 65 cents per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and 2 "sell" or "strong sell." 
* The mean earnings estimate of analysts had risen by about 0.1%
in the last three months. ​
* Wall Street's median 12-month price target for Kaleido
Biosciences Inc is $19​, about 78.2% above​ its last closing
price of $4.15. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Jun. 30 2021  -0.56       -0.57      -0.56     Beat    1.1
 Mar. 31 2021  -0.58       -0.59      -0.58     Beat    2.4
 Dec. 31 2020  -0.49       -0.40      -0.56     Missed  -40.6​
 Sep. 30 2020  -0.59       -0.63      -0.65     Missed  -2.5
 Jun.          -0.58​      -0.59      -0.59     Met     0​
 30​ 2020​                                              
 Mar. 31 2020  -0.64       -0.64      -0.64     Met     0​
 Dec. 31 2019              -0.34      -0.61     Missed  -80.7
 Sep. 30 2019  -0.85       -0.89      -0.74     Beat    16.9
 This summary was machine generated October 29 at 17:24 GMT.  All
figures in US dollars unless otherwise stated